Another solid player in the COVID-19 test kit market is Avalon GloboCare (NASDAQ: AVCO) who recently partnered with Adial Pharmaceuticals (NASDAQ: ADIL) announcing a Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices
As the war against COVID-19 wages on there are a large number of Bio-Tech players racing to get an effective vaccine to market and with the new South African strand there is a concern with who’s will be effective. Another company to keep your eye on is Avalon GloboCare (NASDAQ: AVCO) who are using a proprietary S-Layer “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out.
One of the essential elements in the extracts vertical advancements is the adoption of good manufacturing practices. According to the World Health Organization website, “Good Manufacturing Practice (GMP) is that part of quality assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use.”
Total revenues were $4,907,889 compared to $3,056,431 reported in the same quarter in 2019, representing an increase of over 61%, and a 29.8% increase over the first fiscal quarter of 2021. Gross margin increased to 55% - an increase of 7% over the quarter ended November 30, 2019.
With the potential of a ‘twindemic’ of influenza and SARS-CoV-2 during fall and winter, Avalon GloboCare (NASDAQ: AVCO) is also planning to conjugate the S-layer matrix with an antigenic signature from both SARS-CoV-2 and the influenza virus for one spray that, if proven effective, would provide protective immunity against both viruses. Novarex trades 100X higher price then Avalon and needs the vaccine to be administered twice as opposed to once.
Avalon GloboCare Corp. (NASDAQ: AVCO) a leader in cell-based technology, is launching two major clinical trials to test its blood filtration technology to combat ‘cytokine storms’ induced in some COVID-19 patients and nasal spray vaccine to prevent COVID-19.
Companies that trade on major exchanges have a far better chance of receiving coverage from independent research firms and investment banks, which will ultimately help drive market and investment activity in a particular stock. Most independent research firms and investment banks however do not provide coverage for companies trading on the OTC markets.
CytoDyn Inc. (OTCMKTS: CYDY) may have given one of its last updates as an OTC company yesterday and revealed a number of positive surprises. They could be saying hello NASDAQ, and hello EUA in the course of the next couple of weeks.
Epazz, Inc. (OTC Pink: EPAZ) recently announced that it is working with Greenheart CBD Hemp company in developing their smart contracts for their IEO (Initial Exchange Offering), and the market seems to be reacting well to their entry into this space.
Animal Health, Animal Hospital, arthritis, Biotech, Biotechnology, coronavirus, CoronaVirus Cure, CoronaVirus Vaccine, COVID-19, covid19, Medical, Micro Cap Stocks, OTC Markets, OTC OTCQB, Small Cap Stocks